Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PARG | Q86W56 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802821 | 0.85 | PKM (0.53) | PKMALDH1A1LMNASMN1; SMN2RXFP1 | |
| SCHEMBL4813124 | 0.80 | CYP3A4 (0.63) | PKMALDH1A1PARGLMNASMN1; SMN2 | |
| SCHEMBL4811841 | 0.68 | POLB (0.59) | PKMALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL5940474 | 0.66 | TSHR (0.56) | ALDH1A1LMNASMN1; SMN2RXFP1CYP2C19 | |
| SCHEMBL1278968 | 0.65 | ALDH1A1 (0.61) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL1146000 | 0.65 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2KDM4EKMT2ACYP2C19 | |
| SCHEMBL4040330 | 0.65 | KDM4E (0.75) | PKMALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL23775577 | 0.65 | KDM4E (0.69) | PKMALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL16028245 | 0.65 | ALDH1A1 (0.47) | PKMALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL274924 | 0.65 | TSHR (0.79) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361661-B2 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2008-04-22 | — | — | US | disclosed |
| US-20060173181-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | BHALAY GURDIP | 2006-08-03 | — | — | US | disclosed |
| US-20060106214-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| US-7019136-B2 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS, AG (CH) | 2006-03-28 | — | — | US | disclosed |
| US-6919337-B2 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | NOVARTIS, AG (CH) | 2005-07-19 | — | — | US | disclosed |
| US-20050054660-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | BHALAY GURDIP (GB) | 2005-03-10 | — | — | US | disclosed |
| CN-1176922-C | 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| US-20040038996-A1 | 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors | NOVARTIS AG (CH) | 2004-02-26 | — | — | US | disclosed |
| EP-1268480-B1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | NOVARTIS AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030171384-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | BHALAY GURDIP (GB) | 2003-09-11 | — | — | US | disclosed |
| US-20030114469-A1 | Combinations | COHEN DAVID SAUL (US) | 2003-06-19 | — | — | US | disclosed |
| CN-1420887-A | 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors | NOVARTIS AG (CH) | 2003-05-28 | — | — | CN | disclosed |
| EP-1268480-A1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | Novartis AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001077110-A1 | 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS | NOVARTIS AG (CH) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114469-A1 | Combinations | GPR119, SLC5A1, HMGCR | PKM 1788/4885ALDH1A1 719/4885PARG 2000/4885 |
| US-20060106214-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | PKM 2207/4885ALDH1A1 1219/4885PARG 3084/4885 |
| US-20050054660-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | PKM 2083/4885ALDH1A1 1076/4885PARG 2955/4885 |
| US-20040038996-A1 | 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | PKM 2447/4885ALDH1A1 585/4885PARG 2657/4885 |
| US-20060173181-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors | PDE5A, PDE3A, PDE2A | PKM 2083/4885ALDH1A1 1076/4885PARG 2955/4885 |
| US-20030171384-A1 | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | PDE5A, PDE3A, PDE2A | PKM 2266/4885ALDH1A1 1222/4885PARG 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.